GSK has news on that front today, as well, reporting that the phase 2/3 COSTAR trial of Jemperli with experimental TIM-3 antagonist cobolimab will move into the phase 3 stage on the advice of its ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax ... years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for Cambridge ...

GSK, Am­gen and As­traZeneca re­leased pos­i­tive da­ta sup­port­ing their ri­val drugs in a con­di­tion called chron­ic rhi­nos­i­nusi­tis with nasal polyps, or CR­SwNP.

The Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...

We were therefore interested in understanding how mTOR inhibition affected tumours in KC PTEN mice at cellular level. To test whether rapamycin could induce apoptosis of tumour cells, we performed IHC ...

3.5. Effect of High-Fat Diet on Akt and GSK-3β Phosphorylation Levels To investigate the underlining mechanism of high fat diet induced endothelial injury accompanied by obvious inflammation and ...

GSK’s vaccine generated £3.36bn ($4.35bn) in sales in 2024, as per the company’s financials. According to GlobalData’s Pharma Intelligence Center, Shingrix sales will surpass $5bn by 2030.

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other stocks that Jim Cramer discussed. On Tuesday, Jim Cramer, host of Mad Money, defended the growing wave ...